| Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial J Declercq, KFA Van Damme, E De Leeuw, B Maes, C Bosteels, ... The Lancet Respiratory Medicine 9 (12), 1427-1438, 2021 | 121 | 2021 |
| TIM3+ TRBV11-2 T cells and IFNγ signature in patrolling monocytes and CD16+ NK cells delineate MIS-C L Hoste, L Roels, L Naesens, V Bosteels, S Vanhee, S Dupont, ... Journal of Experimental Medicine 219 (2), 2022 | 87 | 2022 |
| Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): a structured summary of a study protocol for a randomised controlled trial B Maes, C Bosteels, E De Leeuw, J Declercq, K Van Damme, A Delporte, ... Trials 21, 1-2, 2020 | 64 | 2020 |
| Case report: convalescent plasma, a targeted therapy for patients with CVID and severe COVID-19 KFA Van Damme, S Tavernier, N Van Roy, E De Leeuw, J Declercq, ... Frontiers in immunology 11, 596761, 2020 | 57 | 2020 |
| Inflammasomes and IL-1 family cytokines in SARS-CoV-2 infection: from prognostic marker to therapeutic agent J Declercq, E De Leeuw, BN Lambrecht Cytokine 157, 155934, 2022 | 32 | 2022 |
| Loss of GM-CSF-dependent instruction of alveolar macrophages in COVID-19 provides a rationale for inhaled GM-CSF treatment C Bosteels, KFA Van Damme, E De Leeuw, J Declercq, B Maes, ... Cell Reports Medicine 3 (12), 2022 | 27 | 2022 |
| Sargramostim to treat patients with acute hypoxic respiratory failure due to COVID-19 (SARPAC): A structured summary of a study protocol for a randomised controlled trial C Bosteels, B Maes, K Van Damme, E De Leeuw, J Declercq, A Delporte, ... Trials 21, 1-2, 2020 | 27 | 2020 |
| Zilucoplan in patients with acute hypoxic respiratory failure due to COVID-19 (ZILU-COV): A structured summary of a study protocol for a randomised controlled trial J Declercq, C Bosteels, K Van Damme, E De Leeuw, B Maes, ... Trials 21, 1-3, 2020 | 19 | 2020 |
| Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial E De Leeuw, KFA Van Damme, J Declercq, C Bosteels, B Maes, ... Respiratory Research 23 (1), 202, 2022 | 17 | 2022 |
| A complement atlas identifies interleukin-6–dependent alternative pathway dysregulation as a key druggable feature of COVID-19 KFA Van Damme, L Hoste, J Declercq, E De Leeuw, B Maes, L Martens, ... Science Translational Medicine 15 (710), eadi0252, 2023 | 9 | 2023 |
| Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respir Med. 2021 … J Declercq, KFA Van Damme, E De Leeuw, B Maes, C Bosteels, ... DOI: https://doi. org/10.1016/s2213-2600 (21), 00377-5, 0 | 7 | |
| Correction to: Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial B Maes, C Bosteels, E De Leeuw, J Declercq, K Van Damme, A Delporte, ... Trials 21, 2020 | 4 | 2020 |
| Early treatment with inhaled GM-CSF improves oxygenation and anti-viral immunity in COVID-19 induced lung injury–a randomized clinical trial C Bosteels, K Van Damme, E De Leeuw, J Declercq, B Maes, V Bosteels, ... | 3 | 2021 |
| Correction to: Sargramostim to treat patients with acute hypoxic respiratory failure due to COVID-19 (SARPAC): A structured summary of a study protocol for a randomised … C Bosteels, B Maes, K Van Damme, E De Leeuw, J Declercq, A Delporte, ... Trials 21, 2020 | 2 | 2020 |
| How does pneumovirus influence antigen presentation in neonatal mice? E De Leeuw, C Bosteels, D Sichien, K Van Der Borght, J Deckers, ... ERJ Open Research 9 (suppl 10), 2023 | 1 | 2023 |
| Development of human innate immune responses in a humanized mouse model expressing four human myelopoiesis transgenes H Stocks, E De Leeuw, BN Lambrecht, L Vandekerckhove, G van Loo, ... Frontiers in Immunology 15, 1419117, 2024 | | 2024 |
| The role of dendritic cells in respiratory viral infection E De Leeuw, H Hammad European Respiratory Review 33 (172), 2024 | | 2024 |
| Loss of GM-CSF-dependent instruction of alveolar macrophages in COVID-19 provides a rationale for inhaled GM-CSF treatment N Debeuf, C Bosteels, KFA Van Damme, E De Leeuw, J Declercq, ... ERJ Open Research 9 (suppl 10), 2023 | | 2023 |
| Isolation of Conventional Murine Lung Dendritic Cell Subsets E De Leeuw, C Bosteels, BN Lambrecht, H Hammad Asthma: Methods and Protocols, 237-255, 2022 | | 2022 |
| Een ongewone oorzaak van een COPD-exacerbatie: Herpetische tracheobronchitis E De Leeuw, W Verhaeghe, BV Berghe, I Fabry, K Hertveldt, G Joos Tijdschrift voor Geneeskunde 75 (16), 986-989, 2019 | | 2019 |
